New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
08:47 EDTDTV, NDAQ, MHFI, MCK, CAKFY, FOXA, SHLD, TGT, VTR, MYL, ACT, BF.A, BF.B, BEAM, LMCA, CHTR, TWC, PFE, VRX, HCNOn the Fly: Periodicals Wrap
WSJ: DirecTV (DTV) wants Weather Channel fee reduction as apps take hold...Brown-Forman (BF.A, BF.B) may benefit from Beam (BEAM) deal...REUTERS: Malone (LMCA, CHTR) seeks consolidation in Time Warner Cable (TWC) bid...Pfizer's (PFE) generics unit attracts several suitors (VRX, ACT, MYL)...Nasdaq (NDAQ), S&P (MHFI) interested in acquisitions to grow index businesses...BLOOMBERG: McKesson (MCK) considers JV following failure of Celesio (CAKFY) bid...Fox (FOXA) won't participate in network TV’s pilot season...Sears (SHLD) may be cut by S&P...OTHER NEWS: Target's (TGT) problems may benefit security firms, NY Times reports...Ventas (VTR) and Health Care REIT (HCN) held talks, dealReporter reports.
News For B;BEAM;LMCA;CHTR;TWC;PFE;VRX;ACT;MYL;NDAQ;MHFI;MCK;CAKFY;FOXA;SHLD;TGT;VTR;HCN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 10, 2014
08:05 EDTFOXA21st Century Fox, Apollo Global agree to form content joint venture
Subscribe for More Information
08:03 EDTFOXA21st Century Fox, Apollo Global form content joint venture
Subscribe for More Information
07:37 EDTACT, VRXActavis more likely partner than Valeant if Allergan merges, says UBS
Subscribe for More Information
07:16 EDTVRXAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
06:49 EDTSHLDWhirlpool risks from Sears exposure overstated, says BofA/Merrill
BofA/Merrill said Whirlpool (WHR) concerns from Sears (SHLD) exposure are overdone and notes total revenues from Sears are approximately 9% of North American revenues. Shares are Buy rated.
06:42 EDTFOXATime Warner CEO to be questioned on growth plans, NY Post reports
Subscribe for More Information
06:16 EDTVTRVentas upgraded to Buy from Hold at Stifel
Stifel upgraded Ventas to Buy based on valuation. Price target is $70.
October 9, 2014
15:13 EDTLMCALiberty Media CEO says Diller not interested in sale of Expedia, Bloomberg says
Subscribe for More Information
14:48 EDTLMCALiberty Media CEO says discussed exiting Expedia stake, Bloomberg reports
Subscribe for More Information
14:21 EDTVRXAllergan in good position to be patient given raised outlook, says BMO Capital
After speaking with Allergan's (AGN) CEO and CFO, BMO Capital believes the company is increasing its intrinsic value with its raised earnings guidance and that it is in a good position to be patient given that Valeant (VRX) most recent bid represents an 8% discount to Allergan's current share price. BMO said it is reviewing its forecasts for Allergan after the guidance increase, noting that it previously valued Allergan at $230 per share on a standalone basis. The firm maintains its Outperform rating on the stock.
12:28 EDTACT, VRXAllergan price target raised to $230 from $210 at BTIG
BTIG said it expected Allergan to beat the consensus forecast for Q3 EPS, but not by as much as it did, and the firm did not expect the company to raise its future EPS outlook yet again. BTIG feels the stock's move higher indicates Valeant (VRX) or Actavis (ACT) would need to bid above $200 if they hope to buy the company. BTIG maintains its Buy rating on Allergan and raised its price target on the stock to $230 from $210.
11:14 EDTVRX, ACTAllergan raises outlook again as Valeant pursuit continues
Drug maker Allergan (AGN) this morning preannounced stronger than expected results and again raised its fiscal year profit guidance. The beat and raise results come after The Wall Street Journal reported on Tuesday that drug maker Valeant (VRX) and hedge fund Pershing Square intend to raise their previous bid for Allergan by $15 per share to about $191. Meanwhile, also on Tuesday, Reuters said that drug maker Actavis (ACT) plans to make a new merger offer to Allergan, and sources indicated to the news service that Allergan may be willing to consider an offer from Actavis if the bid is for more than $200 per share. WHAT'S NEW: Allergan estimated that its third quarter earnings per share would come in at $1.76-$1.78, versus analysts' consensus estimate of $1.48. The drug maker had previously provided Q3 EPS guidance of $1.44-$1.47. Allergan raised its fiscal 2014 EPS guidance to $6.20-$6.25 from $5.74-$5.80. Analysts' consensus estimate was $5.81. This is the fourth time that Allergan has raised its guidance this year. Allergan said that its markets have been strong around the world, while it is gaining market share in most categories. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that, in the wake of Allergan's guidance increase, the company's price to earnings multiple could expand to 22x its estimated 2016 earnings, up from its current multiple of 19x. In addition to the raised guidance, a potential accretive acquisition by Allergan and the possibility that it will be acquired make such an increase in the multiple "quite possible," Biegelsen contended. He kept an Outperform rating on the stock. WHAT'S NOTABLE: Allergan has reportedly held advanced talks about acquiring another company in the sector, Salix (SLXP), although CNBC's David Faber on October 2 reported that the talks between the two companies about a merger had "cooled considerably." PRICE ACTION: In late morning trading, Allergan rose fractionally to $191.06 while Valeant slid 1.5% to $124.08.
11:00 EDTTWCTime Warner Cable stockholders approve Comcast merger deal
Subscribe for More Information
10:59 EDTTWCTime Warner Cable stockholders approve Comcast merger deal
Subscribe for More Information
10:00 EDTSHLDSears falls, levels to watch
Subscribe for More Information
09:41 EDTTGTBofA/Merrill retail analysts hold an analyst/industry conference call
Subscribe for More Information
08:50 EDTACT, VRXAllergan shares have further upside, says Wells Fargo
Subscribe for More Information
08:18 EDTTWCTime Warner Cable to host special shareholder meeting
Subscribe for More Information
08:01 EDTTGTTarget CEO hands-on with Canadian turnaround, Globe and Mail says
Brian Cornell, the new CEO of Target, told The Globe and Mail in an interview that he is taking a hands-on approach to repairing the company’s Canadian business and that he will travel north on a “regular” basis to oversee the turnaround. Reference Link
05:45 EDTSHLDStocks with implied volatility movement; WLT SHLD
Stocks with implied volatility movement; Walter Energy (WLT) 159, Sears (SHLD) 108 according to iVolatility.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use